This brief document covers your technology, objectives, challenges, market opportunity, and team
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
BRENDA, enzyme data and metabolic information
each 10% reduction in homocysteine is associated with 1.45-2.55 reduction in pulse pressure mmHg in patients undergoing hemodialysis (14)(27)(31) Increased urinary excretion of homocysteine in its sulfonated form (36) Omega-3 fatty acids 200-6,000 mg (~98-2,000 mg EPA/490-1,000 mg DHA) per day, for 1-12 months in patients with hyperhomocysteinemia or elevated homocysteine within normal ranges (8)(11)(13)(17)(18)(19)(25)(30)(42)(43) Reduced homocysteine by 1.18-1.58 mol/L on average using wide dose ranges, as shown in meta-analyses (8)(18) Reduced homocysteine by ~2.5-4.0 mol/L in patients with type II diabetes, patients on hemodialysis, or healthy adults using mid-range doses of 2,000-3,600 mg per day for 1-3 months and up to one year (11)(17)(25)(30)(42)(43) Reduced homocysteine by ~1.6 mol/L over 12 months in patients younger than 65 years, previously suffering from myocardial infarction (13) Adjunct therapy with folic acid, vitamin B6, and vitamin B12 improved efficacy (8)(17) Adjunct aerobic exercise and cognitive stimulation may be required for benefit in some populations, including older adults with mild cognitive impairment (19)
(109) conducted a meta-analysis of clinical trials
Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use
